Beijing Zhongyuan Biopharmaceutical Symposium

On April 13, 2007, Beijing Zhongyuan Ltd. successfully held the Biopharmaceutical Symposium in Beijing Yanshan Hotel. This time, we honorably invited Mr. Jagdish — Biopharmaceutical Technical Expert of BD Asia Pacific, Mr. Zhu Xican — Technical Expert of GE Health Care, and Ms. Zhang Yi—Senior Technical Engineer of 3M, to introduce the leading technologies and trends of the biopharmaceutical industry to the conferees. The honored guests of this symposium were Production Directors and Developing Directors from about 30 biopharmaceutical enterprises in North China. They showed great interests in this symposium.

The symposium was held in a warm atmosphere. Mr. Jagdish — Biopharmaceutical Technical Expert of BD Asia Pacific, presented “The Leading Technologies in the Biopharmaceutical Industry” and “The prospect and the Application of Non-animal Origin Culture Medium”. Mr. Zhu Xican—Technical Expert of GE Health Care, gave a brilliant speech on the technology of micro-carriers which are usually used in high-density culturing of animal cells, with illustrations from his rich practical operation experiences. His speech gave the audiences a deep impression. Ms. Zhang Yi—Senior Technical Engineer of 3M, introduced the application of the depth filtration (Zeta Plus) in the biopharmaceutical industry. After the symposium, many conferees had a deep discussion with the experts on the biopharmaceutical industry and related technologies.

This successful symposium promoted the communication between domestic biopharmaceutical enterprises and the foreign companies, at the same time the intercommunion between these pharmaceutical enterprises and their domestic counterparts. It improves the cooperation between these enterprises, and gives new power to the development of the domestic biopharmaceutical industry.

As a producer’s goods supplier for biopharmaceutical enterprises, Beijing Zhongyuan Ltd. will, as usual, do what she can to promote the development of the Chinese biological industry together with the biopharmaceutical enterprises.

附件: